-
公开(公告)号：US20220000857A1
公开(公告)日：2022-01-06
申请号：US17468103
申请日：2021-09-07
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US11141413B2
公开(公告)日：2021-10-12
申请号：US16093426
申请日：2017-04-17
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US11065240B2
公开(公告)日：2021-07-20
申请号：US15501582
申请日：2015-08-05
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Peter Lamb
IPC: A61K31/47 , A61K38/05 , A61K31/194 , A61K31/69 , A61K31/4965
Abstract: This invention relates to the combination of a C-Met inhibitor and a proteasome inhibitor to treat cancer, particularly multiple myeloma.
-
公开(公告)号：US20200255382A1
公开(公告)日：2020-08-13
申请号：US16787212
申请日：2020-02-11
Applicant: Exelixis, Inc.
Inventor： Gisela Schwab , Dana T. Aftab
IPC: C07D215/233 , A61K31/536
Abstract: This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
-
公开(公告)号：US10736886B2
公开(公告)日：2020-08-11
申请号：US16251617
申请日：2019-01-18
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Thomas Mueller , Aaron Weitzman , Jaymes Holland
IPC: A61K51/00 , A61M36/14 , A61K31/47 , A61K31/4706 , A61K41/00 , A61K45/06 , A61K31/495 , A61K31/4188 , A61N5/10 , A61K31/015
Abstract: Methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments are described, wherein R1 is halo; R2 is halo; and Q is CH or N.
-
Patent Agency Ranking
公开(公告)号：US20160000772A1
公开(公告)日：2016-01-07
申请号：US14699683
申请日：2015-04-29
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Thomas Mueller , Aaron Weitzman , Jaymes Holland
IPC: A61K31/47 , A61N5/10 , A61K31/4188
CPC classification number: A61K31/47 , A61K31/4188 , A61K31/4706 , A61K31/495 , A61K41/00 , A61K45/06 , A61N5/10 , A61K2300/00
Abstract: Methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments are described, wherein R1 is halo; R2 is halo; and Q is CH or N.
Abstract translation: 描述了通过与其它癌症治疗组合施用式I化合物或其药学上可接受的盐或溶剂合物来治疗癌症的方法，其中R1是卤素; R2是卤素; Q为CH或N.
-
公开(公告)号：US20150196545A1
公开(公告)日：2015-07-16
申请号：US14668312
申请日：2015-03-25
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Frauke Schimmoller
IPC: A61K31/47
CPC classification number: A61K31/47
Abstract: This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.
Abstract translation: 本发明涉及用MET和VEGF的双重抑制剂如化合物1治疗癌症，特别是眼部黑色素瘤。
-
公开(公告)号：US20240350477A1
公开(公告)日：2024-10-24
申请号：US18359214
申请日：2023-07-26
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
CPC classification number: A61K31/47 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K31/16 , A61P35/00
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
![Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use](/abs-image/US/2023/09/19/US11760726B2/abs.jpg.150x150.jpg)
公开(公告)号：US11760726B2
公开(公告)日：2023-09-19
申请号：US17212851
申请日：2021-03-25
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Nathan Guz , Stephen Lau , Noel Hamill , Tracy Walker , Jana Galbraith , Simon Yau , Khalid Shah
IPC: C07D215/233 , C07D215/22
CPC classification number: C07D215/233 , C07D215/22 , C07B2200/13
Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
-
公开(公告)号：US11116759B2
公开(公告)日：2021-09-14
申请号：US16142691
申请日：2018-09-26
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Frauke Schimmoller
Abstract: This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.
-
-
-
-
-
-
-
-
-
Search Results
46
records
(took 0.016 seconds)
